Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Novartis | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Novartis

Alcon integration boosts revenue growth

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Novartis 4Q10

4Q Revenues: $14.2 billion (+10%)

4Q Earnings: $2.3 billion (-2%)

FY Revenues: $50.6 billion (+14%)

FY Earnings: $10.0 billion (+18%)

Comments: Pharma sales rose 3% for the quarter to $8.0 billion, and 7% for the year to $30.6 billion. The Sandoz generics unit was up 10% in 4Q10 to $2.4 billion and 14% for FY10 ($8.5 billion). The integration of Alcon added $1.8 billion to 4Q10 sales and $2.4 billion for FY10. The biggest growth in the pharma segment came from the Oncology group, with sales of $2.7 billion (+9%) in 4Q10 and $10.0 billion (+11%) in FY10, driven by Gleevec and Tasigna sales.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters